[1]赵万霞 王何婷 任月秋 崔景秋.糖尿病肾病早期标志物研究新进展[J].国际内分泌代谢杂志,2018,38(03):192-195.[doi:10.3760/cma.j.issn.1673-4157.2018.03.012]
　Zhao Wanxia*,Wang Heting,Ren Yueqiu,et al.Recent progress on the study of early marker for diabetic nephrophy[J].International Journal of Endocrinology and Metabolism,2018,38(03):192-195.[doi:10.3760/cma.j.issn.1673-4157.2018.03.012]
点击复制

糖尿病肾病早期标志物研究新进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
38
期数:
2018年03期
页码:
192-195
栏目:
临床研究
出版日期:
2018-05-20

文章信息/Info

Title:
Recent progress on the study of early marker for diabetic nephrophy
作者:
赵万霞 王何婷 任月秋 崔景秋
300052 天津医科大学总医院内分泌代谢科(赵万霞、王何婷、崔景秋); 100088 北京,中国人民解放军火箭军总医院妇科(任月秋)
Author(s):
Zhao Wanxia*;  Wang Heting;  Ren Yueqiu;  Cui Jingqiu.*
Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin 300052, China
关键词:
糖尿病肾病;  早期标志物;  诊断
Keywords:
Diabetic nephrophy;  Early marker;  Diagnosis
DOI:
10.3760/cma.j.issn.1673-4157.2018.03.012
摘要:
糖尿病肾病是造成终末期肾脏病的主要原因之一并导致糖尿病患者的死亡率不断增加。早期诊断和治疗是改善预后的关键。目前多用微量白蛋白尿和肾小球滤过率综合评价,但微量白蛋白尿的敏感性和特异性不强,肾小球滤过率在正常偏高水平时检测较为困难。因此,近几年很多研究致力于寻找检测糖尿病肾病和预测肾功能下降的早期标志物,包括足细胞标记蛋白、Wilms Tumor-1、胱抑素C、megalin和cubilin、肝脏脂肪酸结合蛋白、尿微小RNA、尿蛋白质组学、中性粒细胞趋化因子、维生素D结合蛋白、骨诱导因子和骨膜蛋白等。
Abstract:
Diabetic nephrophy(DN)constitutes one of the leading causes of end stage renal disease(ESRD)and accounts for a significant increase in morbidity in patients with diabetes. Early diagnosis and treatment is critical in improving patients' prognosis. Currently, the early screening of DN is based both on the level of urinary albumin excretion and glomerular filtration rate(GFR). However, the sensitivity and specificity of microalbuminuria has been challenged, and high-normal level GFR is difficult to be accurately measured. Consequently, great efforts have been made in recent years to identify early markers for the detection of DN and progressive kidney function decline in diabetic patients, including podocalyxin, wilms tumor-1, cystatin C, megalin and cubilin, liver type fatty acid binding protein(L-FABP), urine microRNAs, urine proteomics, monocyte chemoattractant protein-1(MCP-1), vitamin D-binding protein(VDBP), osteoinductive factor(OIF)and periostin,etc.

参考文献/References:


[1] Hara M,Yamagata K,Tomino Y,et al.Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin[J].Diabetologia,2012,55(11):2913-2919.DOI:10.1007/s00125-012-2661-7.
[2] Shoji M,Kobayashi K,Takemoto M,et al.Urinary podocalyxin levels were associated with urinary albumin levels among patients with diabetes[J].Biomarkers,2016,21(2):164-167.DOI:10.3109/1354750X.2015.1118551.
[3] Kubo K,Miyagawa K,Yamamoto R,et al. Detection of WT1 mRNA in urine from patients with kidney diseases[J].Eur J Clin Invest,1999,29(10):824-826.
[4] Kalani A,Mohan A,Godbole MM,et al.Wilm's tumor-1 protein levels in urinary exosomes from diabetic patients with or without proteinuria[J].PLoS One,2013,8(3):e60177.DOI:10.1371/journal.pone.0060177.
[5] Kim SS,Song SH,Kim IJ,et al.Urinary cystatin C and tubular proteinuria predict progression of diabetic nephropathy[J].Diabetes Care,2013,36(3):656-661.DOI:10.2337/dc12-0849.
[6] Thrailkill KM,Nimmo T,Bunn RC,et al.Microalbuminuria in type 1 diabetes is associated with enhanced excretion of the endocytic multiligand receptors megalin and cubilin[J].Diabetes Care,2009,32(7):1266-1268.DOI:10.2337/dc09-0112.
[7] Ogasawara S,Hosojima M,Kaseda R,et al.Significance of urinary full-length and ectodomain forms of megalin in patients with type 2 diabetes[J].Diabetes Care,2012,35(5):1112-1118.DOI:10.2337/dc11-1684.
[8] Nauta FL,Boertien WE,Bakker SJ,et al.Glomerular and tubular damage markers are elevated in patients with diabetes[J].Diabetes Care,2011,34(4):975-981.DOI:10.2337/dc10-1545.
[9] Suh JS,Kim SH,Cho KS,et al.Urinary markers in the early stage of nephropathy in patients with childhood-onset type 1 diabetes[J].Pediatr Nephrol,2016,31(4):623-631.DOI:10.1007/s00467-015-3253-9.
[10] Nielsen SE,Schjoedt KJ,Astrup AS,et al.Neutrophil gelatinase-associated lipocalin(NGAL)and kidney injury molecule 1(KIM1)in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril[J].Diabet Med,2010,27(10):1144-1150.DOI:10.1111/j.1464-5491.2010.03083.x.
[11] Nielsen SE,Reinhard H,Zdunek D,et al.Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients[J].Diabetes Res Clin Pract,2012,97(1):71-76.DOI:10.1016/j.diabres.2012.02.007.
[12] Fu WJ,Xiong SL,Fang YG,et al.Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study[J].Endocrine,2012,41(1):82-88.DOI:10.1007/s12020-011-9509-7.
[13] McClelland A,Hagiwara S,Kantharidis P.Where are we in diabetic nephropathy: microRNAs and biomarkers[J].Curr Opin Nephrol Hypertens,2014,23(1):80-86. DOI:10.1097/01.mnh.0000437612.50040.ae.
[14] Eissa S,Matboli M,Bekhet MM.Clinical verification of a novel urinary microRNA panal: 133b, -342 and -30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis[J].Biomed Pharmacother,2016,83:92-99.DOI:10.1016/j.biopha.2016.06.018.
[15] Szeto CC,Ching-Ha KB,Ka-Bik L,et al.Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases[J].Dis Markers,2012,33(3):137-144.DOI:10.3233/DMA-2012-0914.
[16] Argyropoulos C,Wang K,McClarty S,et al.Urinary microRNA profiling in the nephropathy of type 1 diabetes[J].PLoS One,2013,8(1):e54662.DOI:10.1371/journal.pone.0054662.
[17] Zürbig P,Jerums G,Hovind P,et al.Urinary proteomics for early diagnosis in diabetic nephropathy[J].Diabetes,2012,61(12):3304-3313. DOI:10.2337/db12-0348.
[18] Roscioni SS,de Zeeuw D,Hellemons ME,et al.A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetesmellitus[J].Diabetologia,2013,56(2):259-267.DOI:10.1007/s00125-012-2755-2.
[19] Jalal DI,Maahs DM,Hovind P,et al.Uric acid as a mediator of diabetic nephropathy[J].Semin Nephrol,2011,31(5):459-465.DOI:10.1016/j.semnephrol.2011.08.011.
[20] Scheven L,Joosten MM,de Jong PE,et al.The association of albuminuria with tubular reabsorption of uric acid: results from a general population cohort[J].J Am Heart Assoc,2014,3(2):e000613.DOI:10.1161/JAHA.113.000613.
[21] Jalal DI,Rivard CJ,Johnson RJ,et al.Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study[J].Nephrol Dial Transplant,2010,25(6):1865-1869. DOI:10.1093/ndt/gfp740.
[22] Shoukry A,Bdeer Sel-A,El-Sokkary RH.Urinary monocyte chemoattractant protein-1 and vitamin D-binding protein as biomarkers for early detection of diabetic nephropathy in type 2 diabetes mellitus[J].Mol Cell Biochem,2015,408(1-2):25-35.DOI:10.1007/s11010-015-2479-y.
[23] Fufaa GD,Weil EJ,Nelson RG,et al.Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus[J].Nephrol Dial Transplant,2015,30(4):599-606.DOI:10.1093/ndt/gfv012.
[24] Wang S,Wang Y,Zheng R,et al.Osteoinductive factor is a novel biomarker for the diagnosis of early diabetic nephropathy[J].Int J Clin Exp Pathol,2015,8(3):3110-3115.
[25] Satirapoj B,Tassanasorn S,Charoenpitakchai M,et al. Periostin as a tissue and urinary biomarker of renal injury in type 2 diabetes mellitus[J].PLoS One,2015,10(4):e0124055.DOI:10.1371/journal.pone.0124055.
[26] Jayakumar C,Nauta FL,Bakker SJ,et al.Netrin-1, a urinary proximal tubular injury marker, is elevated early in the time course of human diabetes[J].J Nephrol,2014,27(2):151-157.DOI:10.1007/s40620-014-0055-2.
[27] Ay E,Marakogˇlu K,Kizmaz M,et al.Evaluation of netrin-1 levels and albuminuria in patients with diabetes[J].J Clin Lab Anal,2016,30(6):972-977.DOI:10.1002/jcla.21965.
[28] Tsai SF,Su CW,Wu MJ,et al.Urinary cyclophilin A as a new marker for diabetic nephropathy: a cross-sectional analysis of diabetes mellitus[J].Medicine(Baltimore),2015,94(42):e1802.DOI:10.1097/MD.0000000000001802.
[29] Tsai SF,Hsieh CC,Wu MJ,et al.Novel findings of secreted cyclophilin A in diabetic nephropathy and its association with renal protection of dipeptidyl peptidase 4 inhibitor[J].Clin Chim Acta,2016,463:181-192.DOI:10.1016/j.cca.2016.11.005.
[30] Huang W,Huang J,Liu Q,et al.Neutrophil-lymphocyte ratio is a reliable predictive marker for early-stage diabetic nephropathy[J].Clin Endocrinol(Oxf),2015,82(2):229-233.DOI:10.1111/cen.12576.
[31] Khandare SA,Chittawar S,Nahar N,et al.Study of neutrophil-iymphocyte ratio as novel marker for diabetic nephropathy in type 2 diabetes[J].Indian J Endocrinol Metab,2017,21(3):387-392. DOI:10.4103/ijem.IJEM_476_16.

相似文献/References:

[1].2007年糖尿病新进展学习班将举办[J].国际内分泌代谢杂志,2007,(04):226.
[2]李英,段惠军.Raf/MEK/ERK信号转导通路在糖尿病肾病发生发展中的作用[J].国际内分泌代谢杂志,2007,(04):264.
[3]张红 章向成 朱大龙.炎性反应与糖尿病肾病[J].国际内分泌代谢杂志,2015,(01):49.[doi:10.3760/cma.j.issn.1673-4157.2015.01.012]
　Zhang Hong*,Zhang Xiangcheng,Zhu Dalong..Role of inflammation in diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):49.[doi:10.3760/cma.j.issn.1673-4157.2015.01.012]
[4]邵滢,王秋月.Mir-217/Sirt1通路与糖尿病肾病[J].国际内分泌代谢杂志,2015,(02):124.[doi:10.3760/cma.j.issn.1673-4157.2015.02.014]
　Shao Ying,Wang Qiuyue..Mir-217 / Sirt1 pathway and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):124.[doi:10.3760/cma.j.issn.1673-4157.2015.02.014]
[5]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
　Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[6]任慧雯,王秋月.Epac-Rap1与糖尿病肾病[J].国际内分泌代谢杂志,2015,(03):170.[doi:10.3760/cma.j.issn.1673-4157.2015.03.007]
　Ren Huiwen,Wang Qiuyue..Epac-Rap1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):170.[doi:10.3760/cma.j.issn.1673-4157.2015.03.007]
[7]邵滢,王秋月.MiRNA-150与糖尿病肾病[J].国际内分泌代谢杂志,2015,(03):173.[doi:10.3760/cma.j.issn.1673-4157.2015.03.008]
　Shao Ying,Wang Qiuyue..MiRNA-150 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):173.[doi:10.3760/cma.j.issn.1673-4157.2015.03.008]
[8]陈堃,刘超,陈国芳,等.糖尿病肾病诊断标志物研究进展[J].国际内分泌代谢杂志,2015,(03):176.[doi:10.3760/cma.j.issn.1673-4157.2015.03.009]
　Chen Kun,Liu Chao,Chen Guofang,et al.Urinary biomarkers for diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):176.[doi:10.3760/cma.j.issn.1673-4157.2015.03.009]
[9]任慧雯,王秋月.Vasohibin-1与糖尿病肾病[J].国际内分泌代谢杂志,2015,(04):246.[doi:10.3760/cma.j.issn.1673-4157.2015.04.008]
　Ren Huiwen,Wang Qiuyue..Vasohibin-1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):246.[doi:10.3760/cma.j.issn.1673-4157.2015.04.008]
[10]安丽,王秋月.Visfatin与胰岛素抵抗及糖尿病肾病的发病机制[J].国际内分泌代谢杂志,2015,(04):248.[doi:10.3760/cma.j.issn.1673-4157.2015.04.009]
　An Li,Wang Qiuyue..Visfatin in the pathogenesis of insulin resistance and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):248.[doi:10.3760/cma.j.issn.1673-4157.2015.04.009]

备注/Memo

备注/Memo:

通信作者:崔景秋, Email:cuijingqiu@sina.com
更新日期/Last Update: 2018-03-30